| Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice MF Hebert, X Ma, SB Naraharisetti, KM Krudys, JG Umans, GDV Hankins, ... Clinical Pharmacology & Therapeutics 85 (6), 607-614, 2009 | 260 | 2009 |
| Daily oral GLP-1 receptor agonist orforglipron for adults with obesity S Wharton, T Blevins, L Connery, J Rosenstock, S Raha, R Liu, X Ma, ... New England Journal of Medicine 389 (10), 877-888, 2023 | 102 | 2023 |
| Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice MF Hebert, X Ma, SB Naraharisetti, KM Krudys, JG Umans, GD Hankins, ... Clin Pharmacol Ther 85 (6), 607-614, 2009 | 84 | 2009 |
| The discovery, preclinical, and early clinical development of potent and selective GPR40 agonists for the treatment of type 2 diabetes mellitus (LY2881835, LY2922083, and … C Hamdouchi, SD Kahl, A Patel Lewis, GR Cardona, RW Zink, K Chen, ... Journal of Medicinal Chemistry 59 (24), 10891-10916, 2016 | 56 | 2016 |
| Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin A de la Peña, X Ma, S Reddy, F Ovalle, RM Bergenstal, JA Jackson Journal of Diabetes Science and Technology 8 (4), 821-829, 2014 | 40 | 2014 |
| Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein (a): a randomized dose-ascending clinical trial SE Nissen, H Linnebjerg, X Shen, K Wolski, X Ma, S Lim, LF Michael, ... JAMA 330 (21), 2075-2083, 2023 | 33 | 2023 |
| Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study JP Frias, S Hsia, S Eyde, R Liu, X Ma, M Konig, C Kazda, KJ Mather, ... The Lancet 402 (10400), 472-483, 2023 | 32 | 2023 |
| Imaging spectral device based on multiple volume holographic gratings L Cao, X Ma, Q He, H Long, M Wu, G Jin Optical Engineering 43 (9), 2009-2016, 2004 | 31 | 2004 |
| Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide S Urva, T Quinlan, J Landry, X Ma, JA Martin, CT Benson Clinical Pharmacokinetics 61 (7), 1057-1067, 2022 | 21 | 2022 |
| Discovery of LY3104607: a potent and selective G protein-coupled receptor 40 (GPR40) agonist with optimized pharmacokinetic properties to support once daily oral treatment in … C Hamdouchi, P Maiti, AM Warshawsky, AC DeBaillie, KA Otto, KL Wilbur, ... Journal of Medicinal Chemistry 61 (3), 934-945, 2018 | 21 | 2018 |
| The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis X Ma, D Becker, VC Arena, P Vicini, C Greenbaum The Journal of Clinical Endocrinology & Metabolism 94 (7), 2446-2451, 2009 | 18 | 2009 |
| Pharmacodynamics of glyburide, metformin, and glyburide/metformin combination therapy in the treatment of gestational diabetes mellitus DL Shuster, LM Shireman, X Ma, DD Shen, SK Flood Nichols, MS Ahmed, ... Clinical Pharmacology & Therapeutics 107 (6), 1362-1372, 2020 | 11 | 2020 |
| Experiment on parallel correlated recognition of 2030 human faces based on speckle modulation Y Liao, Y Guo, L Cao, X Ma, Q He, G Jin Optics Express 12 (17), 4047-4052, 2004 | 11 | 2004 |
| Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: a Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple … E Pratt, X Ma, R Liu, D Robins, T Coskun, KW Sloop, A Haupt, C Benson Diabetes, Obesity and Metabolism 25 (9), 2642-2649, 2023 | 10 | 2023 |
| Optimized human regular U-500 insulin treatment improves β-cell function in severely insulin-resistant patients with long-standing type 2 diabetes and high insulin requirements A Mari, J Rosenstock, X Ma, YG Li, JA Jackson Endocrine Practice 21 (12), 1344-1353, 2015 | 8 | 2015 |
| Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: a Phase 1a, blinded, placebo‐controlled, randomized, single‐and multiple‐ascending … E Pratt, X Ma, R Liu, D Robins, A Haupt, T Coskun, KW Sloop, C Benson Diabetes, Obesity and Metabolism 25 (9), 2634-2641, 2023 | 7 | 2023 |
| Pharmacodynamics of metformin in pregnant women with gestational diabetes mellitus and nonpregnant women with type 2 diabetes mellitus DL Shuster, LM Shireman, X Ma, DD Shen, SK Flood Nichols, MS Ahmed, ... The Journal of Clinical Pharmacology 60 (4), 540-549, 2020 | 6 | 2020 |
| Are we guessing glyburide dosage in the treatment of gestational diabetes (GDM)? The pharmacological evidence for better clinical practice MF Hebert, S Naraharisetti, X Ma, KM Krudys, J Umans, GD Hankins, ... Am J Obstet Gynecol 197 (6), S25, 2007 | 5 | 2007 |
| 336-OR: A first-in-human single-and multiple-ascending dose study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel oral nonpeptide Glp-1 … EJ Pratt, X Ma, R Liu, DA Robins, K Sloop, C Benson Diabetes 71 (Supplement_1), 2022 | 4 | 2022 |
| Exposure-schedule study of uniform diffraction efficiency for DSSM holographic storage X Ma, Q He, J Wang, M Wu, G Jin Optics Express 12 (6), 984-989, 2004 | 4 | 2004 |
Paolo ViciniConfo TherapeuticsVerified email at u.washington.edu
